Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders


Sector: Healthcare | Sub-Sector: Drug Manufacturers - Major
Alternate Symbol(s):  BIOYF

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.
Price: $6.99 | Change: $-0.01 | %Change: -0.14%
Volume: 91,072 | Day High/Low: 7.15/6.80 | 52 Week High/Low: 12.82/5.75
View modes: 
5 stars


I can think of a several catalysts over the next few months which might turn the price decline around...a) the issuance of Q2 results (Q2 pharma earnings are usually pretty good and should more
3 stars

RE:Anyone hear how that new generic competition...

BasherSir_Holler wrote: is doing. Are they beginning to eat RX`s lunch.....lame asss bashed bs. It was pointed out several times that RX has been dealing with generics for years and holding its own.  rate and reply
2.5 stars

Anyone hear how that new generic competition...

is doing. Are they beginning to eat RX`s lunch.  rate and reply
5 stars


Also, how about some getting the income tax rate down like others in the space. Re-domicile to low tax country like Bahamas or Belgium... or risk takeover by those that are already there.  rate and reply
0 stars

RE:Anyone hear how that new generic competition...

Sir_H: please check your inbox.  rate and reply
5 stars

RE:RE:Is This Sector Becoming Saturated?

RX is a very small company, only $100 mill mkt cap. Merus is over $300 mill, GUD $600 and Valeant way larger. As stated by RX, this allows the company to focus more on smaller products that the more
0 stars

RE:Is This Sector Becoming Saturated?

FbF1: I think your comment in general is valid, but so far it does not apply to RX.  The company hasn't paid for its pipe and as I recall and that pipe is robust.  There are 2 products in for more
1 star

Is This Sector Becoming Saturated?

There was Paladin Labs. Now there is Valeant, Merus, Biosyent, Knight, etc. etc. Lots of Canadian companies doing a similar may great generics are out there, and will these more
0 stars

Great Buying Opportunity

Current P/E at 30 P/E has averaged over 35 for the past year.  If P/E reverts back to 35 by the end of year with only 35% growth in diluted EPS in the remaining 3 quarters, stock price would be more
0 stars

RE:Cantech Letter

Nice endorsement. We continue to believe RX’s low-risk strategy of building growth will reward investors in the long-term and see recent share price weakness as an opportunity to accumulate more
1 star

Trend Is Your Friend...

RX closing price: April 24,2015    $8.13 May 01,2015     $7.90 May 06,2015     $7.87 May 13,2015     $7.70 May 15,2015     $7.57 52wk high = $12.82       52wk low = $5.35       Cheers!  rate and reply
5 stars

Cantech Letter  rate and reply
0 stars

Below recent closing low today

Hit $7.30 today and that is below the recent closing low of $7.41. Let's see if this level holds. 04/09/15 8.42 8.44 6.96 7.41 356,564 more
0 stars

RE:RE:RE:RE:RE:Obviously it's Sell on News

"Do you really think as a company gets bigger it can continue to grow at 50, 60 or 70%?" When the lower growth finally hits the financial statements it can cause an adjustment in expectations.  rate and reply
0 stars

RE:RE:RE:RE:Obviously it's Sell on News

Sir_Holler wrote: "In what world is 35% revenue growth underwhelming?" BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS more
1 star

Sector Yesterday

Fully agree that the SP should not have dropped as it did yesterday. That said, as can be seen the healthcare sector took a serious hit yesterday. GLTA Sectors that are moving more
1 star

RE:It's a small cap sector problem

The US ended its QE program, the massive bond buying, in October of last year. The end of QE has predicted a major fall in stock prices in the past. We may be witnessing the effects on certain more
4 stars

RE:RE:RE:RE:Obviously it's Sell on News

I think the emphasis on revenue being less than expected by one analyst is overblown. Based on the company's earlier comments, I expected more in the way of international sales, but it appears more
0 stars

RE:RE:RE:Obviously it's Sell on News

"In what world is 35% revenue growth underwhelming?" BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS $0.22 Up 69%; more
3.5 stars

RE:RE:Obviously it's Sell on News

In what world is 35% revenue growth underwhelming? (38% in pharmaceutical) For the rate of EPS growth, this stock is not expensive. Trailing P/E is about 30 for a company that grew earnings 88%. more